Appointments timed in proximity to annual milestones and compliance with screening: randomised controlled trial

Geir Hoff, Michael Bretthauer, Geir Hoff, Michael Bretthauer

Abstract

Objective: To investigate whether appointments for screening timed in proximity to annual milestones (birthdays, Christmas and New Year) may be used as a strategy to improve attendance for screening for colorectal cancer.

Design: Randomised controlled trial.

Setting: City of Oslo (urban) and Telemark county (urban and rural), Norway.

Participants: 12,960 screened adults (64.7% of those invited).

Main outcome measure: Attendance rates for each week and month of assigned appointment.

Results: Attendance rates were significantly higher in December than the rest of the year (72.3% v 64.6%, P<0.001) in adults who received an invitation in the week of their birthday or were assigned to screening in the first or second week after their birthday (67.9% v 64.5%, P=0.007). This effect was most pronounced in the urban population of Oslo. In a multivariable logistic regression model, attendance improved in those who received an invitation in the week of their birthday or were assigned to screening in the first or second week after their birthday (odds ratio 1.15, 95% confidence interval 1.03 to 1.28) and those who were assigned to screening in December (odds ratio 1.45, 1.16 to 1.82).

Conclusion: Attendance rates for screening for colorectal cancer were higher in December and around attendees' birthdays, the latter particularly in an urban population. Compliance with screening programmes may therefore be improved by timing invitations in proximity to annual milestones.

Trial registration: Clinical Trials NCT00119912.

Conflict of interest statement

Competing interests: None declared.

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
    1. Petersen G. Barriers to preventive intervention. Gastroenterol Clin N Am 2002;31:1061-8.
    1. Dulai GS, Farmer MM, Ganz PA, Berbaards CA, Qi K, Doetrich AJ, et al. Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer 2004;100:1843-52.
    1. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark polyp study 1983-1996. Eur J Cancer Prev 2001;10:131-7.
    1. Department of Health and Ageing, Australian Government. National Bowel Cancer Screening Program. . 2008.
    1. Gondal G, Grotmol G, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implications for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-42.
    1. Bretthauer M, Gondal G, Larsen IK, Carlsen E, Eide TJ, Grotmol T, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia. Scand J Gastroenterol 2002;37:568-73.
    1. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline findings of the Italian multicenter randomised controlled trial of “once-only sigmoidoscopy”—SCORE. J Natl Cancer Inst 2002;94:1763-72.
    1. UK Flexible Sigmoidscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomized trial. Lancet 2002;359:1291-300.
    1. Blom J, Liden A, Jeppson B, Holmberg L, Påhlman L. Compliance and findings in a Swedish population screened for colorectal cancer with sigmoidoscopy. Eur J Surg Oncol 2002;28:827-31.
    1. Rasmussen M, Kronborg O, Fenger C, Jørgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol 1999;34:73-8.
    1. Cole SR, Smith A, Wilson C, Turnbull D, Esterman A, Young GP. An advance notification letter increases participation in colorectal cancer screening. J Med Screen 2007;14:73-5.
    1. Hoff G. Colorectal cancer screening: review of the evidence and suggestions on when and how to move on from randomized trials to screening programmes. Scand J Gastroenterol 2004;39:99-103.
    1. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126:1674-80.
    1. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
    1. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
    1. Dybdahl JH, Haug K, Bakkevold K, Olsen KO, Vetvik K. Screening for occult faecal blood loss in a community by means of Hemoccult-II slides and a tetramethylbenzindine test. Scand J Gastroenterol 1984;19:343-9.
    1. Wardle J, Miles A, Atkin W. Gender differences in utilization of colorectal cancer screening. J Med Screen 2005;12:20-7.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere